As­traZeneca pub­lish­es in­ter­im vac­cine da­ta in Lancet, re­veals 10 hos­pi­tal­iza­tions, 1 death in piv­otal con­trol arms

Af­ter read­ing out in­ter­im re­sults in mid-No­vem­ber, As­traZeneca has been hot on the heels of Pfiz­er and Mod­er­na in get­ting its ade­n­ovirus-based vac­cine past reg­u­la­tors’ scruti­ny. Now, the drug­mak­er is turn­ing over those da­ta to the pub­lic in an ef­fort to speed up its re­view.

Among pa­tients dosed with As­traZeneca’s Covid-19 vac­cine AZD1222, there were no re­port­ed hos­pi­tal­iza­tions or se­vere cas­es af­ter 21 days com­pared with 10 pa­tients hos­pi­tal­ized and two clas­si­fied as se­vere in the con­trol arm, ac­cord­ing to in­ter­im da­ta pub­lished Tues­day in The Lancet. There was al­so one re­port­ed death in the con­trol arms of three on­go­ing stud­ies and none among those re­ceiv­ing a two-dose reg­i­men of AZD1222.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER